Supplementary materials include

Supplementary methods Supplementary figures include
S1. Alteration of serum bile acid profile in IBS-D patients. Figure. S2. Fecal microbial structures among control and IBS-D subjects. Figure. S3. Changed luminal BA transformation associated with BA synthetic regulation in mouse with transplantation of IBS-D fecal microbiota. Figure. S4. The effects of Clostridium species on ileal BA feedback control in vivo and hepatic synthetase in vitro. Figure. S5. Effects of taurine-conjugated BAs on protein expressions of FXR, SHP, CYP7A1 and CYP8B1 in hepatocytes.
Supplementary methods
Subject recruitment and sampling
IBS-D patients were recruited through the advertisements or press released in local newspaper. The detail criteria used for patient recruitment are shown as follows:
Inclusion criteria: IBS-D patients were recruited on if they fulfilled the following criteria: 1) meet of Rome IV criteria, including recurrent abdominal pain on average at least 1d/week in the last 3 months; 2) appearance of stool form with at least 25% of loose or watery stools and fewer than 25% of hard stools based on Stool Bristol Score; 3) IBS Symptom Severity Scale (IBS-SSS) over than 75 points at baseline; 4) age of 18 to 65 years; 5) normal colonic evaluation with 5 years by examination of colonoscopy or barium enema; 6) Written informed consent.
Exclusion criteria: Patients were excluded if they have one or more of follows: 1) pregnancy or breast-feeding; 2) medical history of inflammatory bowel diseases, carbohydrate malabsorption, hormonal disorder, known allergies to food additives, and/or any other serious diseases; 3) surgical histories of gallbladder removal, GI tract, and cerebral cranium; 4) having parasitic infections; 5) having suicidal ideas or attempts or aggressive behavior; 6) use of medications known to influence gastrointestinal function, blood pressure and fat.
The sample size of matched healthy controls was expected referred to the around 30% of pooled prevalence of excess total BA excretion in IBS-D population. The recruiting criteria for healthy population is shown as follows:
Inclusion criteria: 1) age of 18-65 years (inclusive); 2) no medical history of metabolic disorders, cardiovascular diseases, neurodegenerative diseases, and gastrointestinal diseases; 4) normal hepatic, renal, and bowel functions within 3 years; 4) no drug taken history for chronic diseases, metabolic diseases, cardiovascular and cerebrovascular diseases, psychiatric illness, disease of immune system, and other serious diseases within 1 year; 5) written informed consent.
Exclusion criteria: 1) pregnancy or breast-feeding; 2) surgical histories of gallbladder removal, GI tract, and cerebral cranium; 3) having parasitic infections; 4) use of medications known to influence gastrointestinal transit, blood pressure and fat.
A questionnaire of IBS symptoms contained IBS-SSS, defecation frequency within a day and Bristol Stool Form Scale was required to complete when the interview with physicians. Fecal consistency of individuals was assessed by the score of the Bristol Stool Form Scale. Meanwhile, another dietary questionnaire that recorded complete diet information and dietary habits within past three months was also required to be completed upon subject recruitment and, those with specific dietary habits, such as alcohol consumption or a completely vegetable-based diet, were excluded as well. Participants were instructed to provide fasting blood samples and morning first feces for analyzing 1) serum biochemical indices and stool culture test (conducted by Chan & Hou Medical Laboratories Ltd, Hong Kong); 2) bile acid (BA) profiles and metagenomics. They were also required to stop using antibiotics, probiotics, prebiotics and other microbiota-related supplements at least one month before sampling.
Targeted profiling of bile acids and C4 based on UPLC/MS
Chemicals and reagents. A total of 36 BA metabolites, including cholic acid (CA), ω-muricholic acid (ωMCA), α-muricholic acid (αMCA), β-muricholic acid (βMCA), hyocholic acid (HCA), hyodeoxycholic acid (HDCA), chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), deoxycholic acid (DCA), isodeoxycholic acid (IsoDCA), isolithocholic acid (IsoLCA), 7ketodeoxycholic acid (7-KDCA), 6-ketolithocholic acid (6-KLCA), 7-ketolithocholic acid (7-KLCA), and 0.1% FA in acetonitrile (B). The gradient program was: 25% to 40% B for the first 6 min, 40% to 70% B for 14 min, 70% to 100% B for 0.1 min, held at 100% B for 2.9 min, then re-equilibration at 25% B for 0.1 min, and held at 25% B for 2.9 min. The column temperature was maintained at 45 C. The capillary voltage of mass spectrometer was 3.5 kV and 4 kV in positive and negative modes. The acquisition data was analyzed using Agilent MassHunter Workstation Software for peak integration, calibration equations and quantification of individual BAs.
Measurement of bacterial BA-transforming activities
The BA-transforming activities of gut bacteria isolated from human feces or mouse cecal contents were assessed in vitro by quantifying the BA products and substrates for each transforming action using LC/MS. The concentration of supplemented BA substrates was referred to the level of total BAs in feces of human beings. In details, mixed bacteria were individually extracted from human feces using 10-fold sterile PBS with differential centrifugation. A volume of 1mL of bacterial reaction mixture, containing bacterial extracts (diluted as 0.1 of the final OD600 value), BHI medium (BD Biosciences) and 5 mM BA substrate (GCDCA, CDCA or CA), were prepared and shaken continuously at 37°C for 24 hours. Then, BA metabolites were extracted from the culture medium using 3-fold methanol for LC/MS-based quantitative analysis. The ratio of CDCA to GCDCA represented the level of bacterial deconjugation, the ratio of UDCA to CDCA and DCA to CA were used for evaluating bacterial 7-HSDH and 7α-dehydroxylating levels, respectively. For mouse BAtransforming activity analysis, Mixed bacteria were isolated from cecal contents, and the bacterial reaction mixture with 5 mM BA substrate (TCA, CDCA or CA) were prepared as mentioned above.
The level of bacterial deconjugation was evaluated by the ratio of TCA to CA, while bacterial 7-HSDH and 7α-dehydroxylating levels were tested with the ratio of UDCA to CDCA and the ratio of DCA to CA, respectively.
Quantitative real-time PCR analysis of bacterial and host genes
Total DNA was extracted from cecal contents (100 mg) of FMT or Clostridium-treated mice for specific bacteria analysis using real-time PCR detection. Briefly, TB Green Premix detection kits (Cat# RR820B, Takara) were purchased for preparation of qPCR reaction mixture, containing DNA template (50ng), 0.5µM each DNA oligonucleotide primers (Invitrogen), and TB Green Master Mix (2X). Bacterial genes were amplified using a real-time PCR cycler (ViiA TM 7Dx Instrument, Applied Biosystems). The relative levels of each bacterium from each DNA samples was normalized to the total bacterial expression. Moreover, total RNA samples were individually isolated from the hepatic and ileum tissues of experimental mice using TissueLyzer (Qiagen) with Trizol reagent (Invitrogen).
The cDNAs were produced from RNA samples using the SuperScript® First-Strand synthesis system (Invitrogen). Quantitative real-time PCR detection was performed on the ViiA™ 7 Real-Time PCR System, and analysis of target gene expression was processed with the ΔΔCT method.
Oligonucleotide primers for bacteria and host genes related to BA metabolism are summarized as below.
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